Abstract
The management of pyoderma gangrenosum (PG) remains a formidable clinical challenge due to its complex, multipathway immunopathogenesis. Although conventional steroid therapy and advanced biologic agents have improved outcomes, a substantial proportion of patients, particularly those with severe, progressive ulceration, exhibit treatment‐refractory disease, highlighting a critical unmet need for novel strategies capable of network‐level immune modulation. To address this, we designed and implemented a self‐regulating, integrative meta‐therapeutic system centered on a nanostructured, herbo‐metallic core of traditionally processed mercury sulfide (HgS) called Linga Chenduram, a compound characterized by its stable crystalline lattice and a toxicokinetic profile favoring particulate clearance. This system synergistically combines the nanocore with adjunctive phytocompounds (Allium sativum and Aloe vera), a transient low‐dose glucocorticoid pulse, and an optimized anti‐inflammatory, antioxidant‐rich physiological milieu delivered within a stress‐free environment. In a cohort of four patients with PG refractory to conventional immunosuppressants, this 30‐day protocol elicited a rapid and profound clinical response. Objective metrics demonstrated a mean ulcer area reduction exceeding 61% by Day 30, progressing to complete and sustained re‐epithelialization in all subjects. This robust cutaneous healing occurred concurrently with the normalization of systemic inflammation (C‐reactive protein) and a significant restoration of functional capacity, evidenced by a mean improvement of 35 points on the Anterior Knee Pain Scale. Critically, clinical remission was maintained throughout a 6‐month surveillance period, establishing a definitive steroid‐sparing effect. We propose this multisystem improvements emerge from rational polypharmacology, wherein the nanoengineered HgS core serves as a pivotal immunomodulatory node, potentially engaging master regulatory pathways like NF‐κB to disrupt dysregulated cytokine circuitry. It transcends conventional combination therapy, introducing a paradigm for managing refractory autoinflammation through integrative systems and compelling a rigorous reappraisal of pharmaceutically refined traditional nanomedicines. This preliminary evidence establishes a compelling rationale for future research to deconstruct the system’s architecture and validate its therapeutic potential.